Roche Pharmaceuticals Shanghai has announced that its anti-Human Epidermal Growth Factor Receptor 2 (HER2) drug, Herceptin® (trastuzumab), continues to achieve significant breakthroughs in the treatment of gastric cancer following its successful use in HER2-positive breast cancer treatment. Herceptin® combination chemotherapy has been officially approved by the Chinese State Food and Drug Administration for the first-line treatment of HER2-positive metastatic gastric cancer. This means that gastric cancer treatment in China has entered the era of molecular targeting, and more patients with HER2-positive gastric cancer will benefit from it. In recent years, with the changes of environment and diet structure, the incidence rate of gastric cancer in China has climbed significantly, which is especially obvious in some developed cities, and the incidence rate has climbed significantly in recent years. Stomach cancer increases by 400,000 annually, and 70% of patients are in urgent need of effective treatment programs Cancer is the number one killer in modern cities, and according to WHO, the number of cancer deaths worldwide is about more than 7 million each year, among which stomach cancer ranks high as the second cause of death from various types of cancer. In recent years, with the changes of environment and diet structure, the incidence of gastric cancer in China has been on the rise, which is especially significant in some developed cities. According to the Beijing Cancer Institute, the incidence rate of gastric cancer in Beijing is 18.995 per 100,000, and it is showing a high trend. As one of the most common malignant tumors in China, gastric cancer is insidious in the early stage, and about 70% of patients are diagnosed in the middle and late stage. Due to the lack of effective treatment, the overall treatment effect of gastric cancer is still unsatisfactory, and its 5-year survival rate is about 5-20%, and the overall average survival time is less than 1 year. Stomach cancer patients are expected to receive individualized treatment with clear staging The latest research shows that stomach cancer, like breast cancer, has “yin and yang”, which can be divided into negative and positive according to HER2 status. If a patient is HER2-positive, it means that the patient has excess HER2 protein on the surface of cancer cells, which will stimulate the cancer cells to grow wildly and increase their aggressiveness. Such patients’ disease is prone to recurrence and metastasis, and patients generally have a poor prognosis. The results of a phase III international clinical study called ToGA showed that about 16% of gastric cancer patients were HER2-positive. 35% of HER2-positive patients with advanced, inoperable disease had a 35% lower risk of death and improved quality of life after treatment with Herceptin. Early detection of HER2 gene, early classification and targeted treatment will become the main direction of standardized treatment for gastric cancer in the future.